Article

Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells

Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Cell stem cell (Impact Factor: 22.15). 02/2010; 6(2):141-52. DOI: 10.1016/j.stem.2010.01.001
Source: PubMed

ABSTRACT eNOS expression is elevated in human glioblastomas and correlated with increased tumor growth and aggressive character. We investigated the potential role of nitric oxide (NO) activity in the perivascular niche (PVN) using a genetic engineered mouse model of PDGF-induced gliomas. eNOS expression is highly elevated in tumor vascular endothelium adjacent to perivascular glioma cells expressing Nestin, Notch, and the NO receptor, sGC. In addition, the NO/cGMP/PKG pathway drives Notch signaling in PDGF-induced gliomas in vitro, and induces the side population phenotype in primary glioma cell cultures. NO also increases neurosphere forming capacity of PDGF-driven glioma primary cultures, and enhances their tumorigenic capacity in vivo. Loss of NO activity in these tumors suppresses Notch signaling in vivo and prolongs survival of mice. This mechanism is conserved in human PDGFR amplified gliomas. The NO/cGMP/PKG pathway's promotion of stem cell-like character in the tumor PVN may identify therapeutic targets for this subset of gliomas.

Download full-text

Full-text

Available from: Cameron Walter Brennan, Aug 25, 2015
0 Followers
 · 
144 Views
    • "Thus targeting NO production constitutes a potential way to diminish BTSC maintenance and might increase patient survival [103]. The cellular response of NO in BTSCs was shown to be mainly regulated by the Notch self-renewal pathway [103]. In addition, endothelial cells are known to produce Notch ligands [105]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a lot of experimental evidence that brain tumors might be sustained by a subpopulation of immature cells, so-called brain tumor stem cells (BTSCs), which do not only drive tumor formation but are highly resistant to conventional therapies. Recent findings suggest a critical role of the molecular and cellular tumor microenvironment in which these cells reside for the maintenance of stem cell properties and therapy resistance. However, detection of different BTSC phenotypes even in the same patient tumor and the observation of a marked plasticity due to instability of the BTSC phenotype caused by the environmental niche have led to a controversial discussion on the validity of the cancer stem cell concept. What complicates the situation even more is that there are different types of niches and little is known about the interplay of the niche components with one another and with different types of BTSCs in the context of stem cell maintenance. In this article we review our current knowledge on different BTSC phenotypes and the cellular components and physiology of the niche in which these cells reside. In addition, we will summarize the molecular and functional interaction of niche cells and niche conditions and how this impacts on BTSC maintenance.
    Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 08/2014; 14(8). DOI:10.2174/1871520614666140825103636 · 2.94 Impact Factor
  • Source
    • "Strong activation of the wnt pathway, which is also very important for the normal intestinal stem cells, results in the conversion of the differentiated cells into a more stem cell-like state [58] [59]. Similarly, in glioblastoma, nitric oxide that is produced by the tumor vasculature activates Notch signaling and induces the expression of the stem cell marker nestin in the cells located in the perivascular niche [60]. Induction of dedifferentiation by inflammation or other environmental stimuli has also major "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor cell plasticity is an event that has been observed in several malignancies. In fact, most of the solid tumors are characterized by cellular heterogeneity and undergo constant changes as the tumor develops. The increased plasticity displayed by these cells allows them to acquire additional properties, enabling epithelial-mesenchymal transitions, dedifferentiation and the acquisition of stem cell-like properties. Here we discuss the particular importance of an inflammatory microenvironment for the bidirectional control of cellular plasticity and the potential for therapeutic intervention.
    FEBS letters 06/2014; DOI:10.1016/j.febslet.2014.06.019 · 3.34 Impact Factor
  • Source
    • "In addition to SLRCs converting to a differentiated sensitive state, our model assumes that a fraction of DSCs may be capable of reverting to become SLRCs after exposure to ionizing radiation (Bleau et al., 2009; Charles et al., 2010; Chen et al., 2012; Li et al., 2009; Pistollato et al., 2010). The rate at which DSCs revert to a stem-like state is given by n, and the fraction of DSCs that can revert is given by g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glioblastomas (GBMs) are the most common and malignant primary brain tumors and are aggressively treated with surgery, chemotherapy, and radiotherapy. Despite this treatment, recurrence is inevitable and survival has improved minimally over the last 50 years. Recent studies have suggested that GBMs exhibit both heterogeneity and instability of differentiation states and varying sensitivities of these states to radiation. Here, we employed an iterative combined theoretical and experimental strategy that takes into account tumor cellular heterogeneity and dynamically acquired radioresistance to predict the effectiveness of different radiation schedules. Using this model, we identified two delivery schedules predicted to significantly improve efficacy by taking advantage of the dynamic instability of radioresistance. These schedules led to superior survival in mice. Our interdisciplinary approach may also be applicable to other human cancer types treated with radiotherapy and, hence, may lay the foundation for significantly increasing the effectiveness of a mainstay of oncologic therapy. PAPERCLIP:
    Cell 01/2014; 156(3):603-16. DOI:10.1016/j.cell.2013.12.029 · 33.12 Impact Factor
Show more